Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults

Muller, Claude P.; Fack, Fred; Damien, Benjamin; Bouche, Fabienne B.

doi:10.1016/s0264-410x(02)00606-0

Cited by 20 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant advances to the oral delivery of plant cell‐encapsulated proteins have been made in the last decade. Daniell and others showed that oral delivery of plants that produce recombinant vaccines can be successful (Alvarez et al ., ; Arlen et al ., ; Boyhan and Daniell, ; Daniell et al ., , ; Kapusta et al ., ; Kwon et al ., ,b; Muller et al ., ; Sherman et al ., ; Verma et al ., ) in addition to the delivery of small enzymes that do not require post‐translational modifications (Arakawa et al ., ; Boyhan and Daniell, ; Kwon et al ., ; Ruhlman et al ., ; Xie et al ., ). The current study, however, is the first successful attempt to orally deliver a plant cell‐encapsulated glycosylated enzyme used for ERT.…”

Section: Discussionmentioning

confidence: 99%

Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease

Shaaltiel

Gingis-Velitski

Tzaban

et al. 2015

Plant Biotechnology Journal

View full text Add to dashboard Cite

Summary Gaucher's disease (GD), a lysosomal storage disorder caused by mutations in the gene encoding glucocerebrosidase (GCD), is currently treated by enzyme replacement therapy (ERT) using recombinant GCD that is administered intravenously every 2 weeks. However, intravenous administration includes discomfort or pain and might cause local and systemic infections that may lead to low patient compliance. An orally administered drug has the potential to alleviate these problems. In this study, we describe the potential use of plant cells as a vehicle for the oral delivery of recombinant human GCD (prGCD) expressed in carrot cells. The in vitro results demonstrate that the plant cells protect the recombinant protein in the gastric fluids and may enable absorption into the blood. Feeding experiments, with rat and pig as model animals, using carrot cells containing prGCD, show that active recombinant prGCD was found in the digestive tract and blood system and reached both, liver and spleen, the target organs in GD. These results demonstrate that the oral administration of proteins encapsulated in plant cells is feasible. Specifically, carrot cells containing recombinant human prGCD can be used as an oral delivery system and are a feasible alternative to intravenous administration of ERT for GD.

show abstract

Section: Discussionmentioning

confidence: 99%

Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease

Shaaltiel

Gingis-Velitski

Tzaban

et al. 2015

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Carrot is now used as a means to deliver vaccine which needs to be introduced orally. Another benefit of this is that no cooking is required while using a vegetable like carrot [38]. Lettuce (Lactuca sativa), celery cabbage (Brassica rapa var.…”

Section: Transgenic Plants For the Production Of Plant Derived Ediblementioning

confidence: 99%

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

2016

J Coast Life Med

View full text Add to dashboard Cite

“…High levels of recombinant protein expression were observed in proplastids of cultured carrot cells . Oral delivery of the therapeutic proteins via edible carrot preserved the structural integrity of their target proteins as no cooking is needed (Muller et al, 2003). Other vegetable crops like lettuce (Lactuca sativa), celery cabbage (Brassica rapa var.…”

Section: Transgenic Plants For the Production Of Plant Derived Vaccinesmentioning

confidence: 99%

Transgenic plants as green factories for vaccine production

Kumar¹,

Raja²,

Wani³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Edible vaccine technology represents an alternative to fermentation based vaccine production system. Transgenic plants are used for the production of plant derived specific vaccines with native immunogenic properties stimulating both humoral and mucosal immune responses. Keeping in view the practical need of new technology for production and delivery of inexpensive vaccines, especially in developing world, plant derived edible vaccines is the best option in hand to combat infectious diseases. Plant derived vaccine is easy to administer, cost effective, readily acceptable, have increased safety, stability, versatility and efficacy. Several plant derived vaccines are under research, some are under clinical trials for commercial use. Like most biotechnology products, the IP situation for edible vaccines is complex as IP rights influence every stage of vaccine development.

show abstract

Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults

Cited by 20 publications

References 19 publications

Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease

Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

Transgenic plants as green factories for vaccine production

Contact Info

Product

Resources

About